- The annual American Society of Hematology meeting is due to start today in New Orleans, where new treatments for chronic lymphocytic leukemia from Gilead Sciences (NASDAQ:GILD), Pharmacyclics Inc. (NASDAQ:PCYC), Infinity Pharmaceuticals (NASDAQ:INFI), Roche (OTCQX:RHHBY) and others will be a focus.
- Analysts forecast that the drugs will collectively generate up to $9B a year in annual revenue by 2020.
Leukemia drugs in focus at hematology meeting
Recommended For You
More Trending News
About GILD Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
GILD | - | - |
Gilead Sciences, Inc. |